Get Premium to unlock powerful stock data
Acumen Pharmaceuticals Inc logo

Acumen Pharmaceuticals Inc

$ 3.47 -0.02 (-0.57%) 08:08 PM EST
P/E:
At Loss
P/B:
0.62
Market Cap:
$ 140.54M
Enterprise V:
$ -52.90M
Volume:
121.14K
Avg Vol (2M):
205.56K
Volume:
121.14K
Market Cap $:
140.54M
PE Ratio:
At Loss
Avg Vol (2-Month):
205.56K
Enterprise Value $:
-52.90M
PB Ratio:
0.62
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Acumen Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
427 Park Street, Charlottesville, VA, USA, 22902
Description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.98
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 50.77
9-Day RSI 46.27
14-Day RSI 43.8
6-1 Month Momentum % -59.84

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 38.6
Quick Ratio 38.6
Cash Ratio 37.74

Dividend & Buy Back

Name Current Vs Industry Vs History
Name Current Vs Industry Vs History
ROE % -134.16
ROA % -80.49
ROIC % -93.15
ROC (Joel Greenblatt) % 5420.17
ROCE % 53.4

Financials (Next Earnings Date:2022-08-16 Est.)

ABOS's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:ABOS

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -2.095
Beta 0
Volatility % 0
14-Day RSI 43.8
14-Day ATR ($) 0.34413
20-Day SMA ($) 3.7185
12-1 Month Momentum % 0
52-Week Range ($) 3.02 - 26.98
Shares Outstanding (Mil) 40.5

Piotroski F-Score Details

Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Acumen Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More